Attorneys at Atkins & Markoff have recently began investigating and pursuing lawsuits against GlaxoSmithKline (GSK), the global manufacturer of the anti-nausea medication Zofran. Zofran is commonly prescribed to women during their first-trimester to treat morning sickness. Recent studies have shown that pregnant women who took Zofran are at a higher risk for giving birth to children with birth defects. Here at Atkins & Markoff, our personal injury lawyers are committed to working diligently with those who have been affected negatively by Zofran. Alarmingly, the FDA never approved Zofran for morning sickness, and GSK paid a $2 billion settlement in a civil lawsuit that involved allegations that GSK illegally promoted Zofran to be prescribed to pregnant women for morning sickness. If you or a loved one has been prescribed Zofran while pregnant, please contact Atkins & Markoff immediately.
Birth Defects Associated With Zofran
Recent studies have shown that expectant women are at a higher risk of delivering children with the following birth defects and pregnancy risks:
- Cleft lip
- Cleft palate
- Congenital heart defects, including septal defects or holes in the heart
- Kidney malformations
- Abnormal or potentially fatal heart rhythm
- Fetal growth restriction
- Life-threatening pregnancy complications
- Serotonin syndrome
If your child was born with one of the above listed birth defects, please contact our Oklahoma personal injury law office today. We will be able to go over your case in detail and determine whether or not you have the right to pursue legal action against GSK for your child’s injuries and the emotional trauma you have sustained.
In December 2012, a recall was issued for intravenous Zofran. Also at this time, the FDA issued additional warnings about the severe, life-threatening heart rhythm disorders associated with the drug. The FDA-issued recall was pushed forward as a result of a safety study published by GSK in July 2012.
To learn more about the dangers associated with Zofran, please contact Atkins & Markoff today.